Clinical Trials Directory

Trials / Completed

CompletedNCT05455879

Impact of Antenatal Corticosteroid Therapy on Postnatal Surfactant Use in Preterm Infants

Impact of the Number of Doses of Antenatal Corticosteroid Therapy on the Number of Doses of Surfactants Postnatal in Preterm Infants

Status
Completed
Phase
Study type
Observational
Enrollment
145 (actual)
Sponsor
Hôpital NOVO · Academic / Other
Sex
All
Age
37 Weeks
Healthy volunteers
Not accepted

Summary

No study has shown that two doses of corticosteroids are more effective than a single dose in lung maturation and prevention of hyaline membrane disease (HMD) The aim of this study is to assess the impact of the number of doses on the severity of HMD.

Detailed description

Respiratory distress syndrome (RDS), formerly known as hyaline membrane disease, is a common problem in preterm infants. This disorder is caused primarily by deficiency of pulmonary surfactant in an immature lung. RDS is a major cause of morbidity and mortality in preterm infants. Surfactant therapy has been shown to significantly reduce neonatal and infant mortality. Corticosteroids are given antenatal, and then surfactant is given, along with corticosteroids, postnatal. A single course of corticosteroids is recommended for pregnant women between 24 weeks and 34 weeks of gestation who are at risk of preterm delivery within 7 days, including those with ruptured membranes and multiple pregnancies. Betamethasone is recommended as the steroid of choice, to be administered in two doses of 12 mg given intramuscularly 24 hours apart.

Conditions

Interventions

TypeNameDescription
OTHERImpact of antenatal corticosteroid therapy on surfactants use postnatalIntervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal

Timeline

Start date
2022-06-20
Primary completion
2022-07-05
Completion
2022-07-05
First posted
2022-07-13
Last updated
2024-09-19

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05455879. Inclusion in this directory is not an endorsement.